Pharmaceutical companies are in the news again being accused of unreasonable price hikes. This time it's Actavis UK, who have been accused by the NHS of overcharging for a "lifesaving" drug by raising the price more than 12 thousand percent. This follows similar situations such as Pfizer being charged a record 107 million dollar fine for allegedly overcharging for an epilepsy treatment, and the Martin Shkreli scandal, when the U.S. Pharmaceutical Executive bought the rights to Daraprim, and raised the price more than 50-fold. Share Radio's Matt Cox has been investigating these price hikes. He spoke to Dr Amit Roy pharmaceutical analyst and founder of independent investment research firm Foveal.